cyclo-Tris[μ-5-(2-pyrid­yl)pyrazol-1-ido-κ3 N 1,N 5:N 2]tris­ilver(I)

In the title compound, [Ag3(C8H6N3)3], the asymmetric unit contains three silver cations and three depronated 5-(2-pyrid­yl)pyrazol-1-ide ligands. Each silver cation is chelated by one 5-(2-pyrid­yl)pyrazol-1-ide ligand, which also acts as a bridging ligand towards the next silver ion via the second pyrazole N atom. In summary, three silver cations and three deprotonated 3-(2-pyrid­yl)-1H-pyrazole ligands produce a macrocyclic trimeric coordination oligomer that exhibits an almost planar conformation (mean deviation 0.1483 Å). In addition, short non-bonding Ag⋯Ag inter­actions [3.127 (2) Å] are observed

Di-n-butyl 5-amino­isophthalate

The title compound, C16H23NO4, is essentially planar except for the last two C atoms in each n-butyl group (r.m.s. deviation from the least-squares plane = 0.02 Å for 17 non-H atoms). In the crystal, inter­molecular N—H⋯O hydrogen bonds between the amine and carbonyl groups link the mol­ecules into one-dimensional chains

Bis(μ-biphenyl-2,2′-dicarboxyl­ato)bis­[(2,2′-bipyridine)copper(II)]

The title compound, [Cu2(C14H8O4)2(C10H8N2)2], was obtained by solvothermal synthesis. The CuII atom is coordinated by one chelating 2,2′-bipyridine ligand and two carboxyl groups from different biphenyl-2,2′-dicarboxyl­ate ligands, leading to a distorted octahedral environment. Each carboxyl­ate group makes one short Cu—O bond [1.9608 (14) and 1.9701 (14) Å] and one longer Cu—O contact [2.4338 (17) and 2.5541 (17) Å] to each CuII atom. The biphenyl-2,2′-dicarboxyl­ate ligands bridge between CuII atoms, forming a dinuclear complex around a crystallographic inversion centre

Bis(6-meth­oxy-2-{[tris­(hydroxy­meth­yl)methyl-κO]imino­meth­yl}phenolato-κ2 N,O 1)nickel(II) dihydrate

In the title compound, [Ni(C12H16NO5)2]·2H2O, the NiII atom is coordinated by four O atoms and two N atoms from the two 6-meth­oxy-2-{[tris­(hydroxy­meth­yl)meth­yl]imino­meth­yl}phenolate ligands in a distorted octa­hedral coordination geometry. O—H⋯O hydrogen bonds link the complexes and uncoordinated water mol­ecules into two-dimensional networks parallel to (001)

Diaqua­[5,5′-dicarb­oxy-2,2′-(propane-1,3-di­yl)bis­(1H-imidazole-4-carboxyl­ato)]manganese(II)

The complex mol­ecule of the title compound, [Mn(C13H10N4O8)(H2O)2] or [Mn(H4pbidc)(H2O)2] (H6pbidc = 2,2′-(propane-1,3-di­yl)bis­(1H-imidazole-4,5-dicarb­oxy­lic acid), has 2 symmetry with the twofold rotation axis running through the Mn2+ cation and the central C atom of the propanediyl unit. The cation is six-coordinated by two N atoms and two O atoms from one H4pbidc2− anion and two water O atoms in a considerably distorted octa­hedral coordination. In the crystal, adjacent mol­ecules are linked through O—H⋯O and N—H⋯O hydrogen bonds into a three-dimensional network

Lithium diaqua­magnesium catena-borodiphosphate(V) monohydrate, LiMg(H2O)2[BP2O8]·H2O, at 173 K

The crystal structure of LiMg(H2O)2[BP2O8]·H2O consists of tubular structural units, built from tetra­hedral ∞ 1{[BP2O8]3−} borophosphate ribbons and (LiO4)n helices running along [001], which are inter­connected by MgO4(H2O)2 octa­hedra, forming a three-dimensional network structure with one-dimensional channels along [001] in which the water mol­ecules are located. The water mol­ecule in the channel is significantly displaced by up to 0.3 Å from the special position 6b (..2) to a half-occupied general position. Mg, B and one Li atom all lie on twofold axes. Of the two Li positions, one is at a special position 6b (..2), while the other is at a general position; both are only half-occupied

High-quality multi-wavelength quantum light sources on silicon nitride micro-ring chip

Multi-wavelength quantum light sources, especially at telecom band, are extremely desired in quantum information technology. Despite recent impressive advances, such a quantum light source with high quality remains challenging. Here we demonstrate a multi-wavelength quantum light source using a silicon nitride micro-ring with a free spectral range of 200 GHz. The generation of eight pairs of correlated photons is ensured in a wavelength range of 25.6 nm. With device optimization and noise-rejecting filters, our source enables the generation of heralded single-photons - at a rate of 62 kHz with $g^{(2)}_{h}(0)=0.014\pm0.001$, and the generation of energy-time entangled photons - with a visibility of $99.39\pm 0.45\%$ in the Franson interferometer. These results, at room temperature and telecom wavelength, in a CMOS compatible platform, represent an important step towards integrated quantum light devices for the quantum networks.Comment: 7 pages, 4 figure

Cestrum nocturnum

Most of the existing chemotherapeutic drugs have plenty of side effects. Chinese herbal medicine has been used for pharmaceutical and dietary therapy for thousands of years with more effective and fewer side effects. Cestrum nocturnum (CN) has long been used to treat digestive diseases for centuries in China. Our previous study first proved that the n-butanol part isolated from the flowers of CN produced an inhibitory effect on the proliferation of malignant cells. However, the fractions responsible for the antiproliferation effect of n-butanol part from CN flowers and related mechanisms remain unknown. Thus, in this study, we extracted fractions C4 and C5 from n-butanol part of CN flowers and investigated their immune toxicity and antitumor activities. It was found that fractions C4 and C5 exhibited great cytotoxicity to cancer cell lines but had low immune toxicity towards T and B lymphocytes in vitro. The tested fractions also attenuated proliferation and induced apoptosis at G0/G1 and G2/M phases in Bel-7404 cells through inducing DNA damage and inhibiting topoisomerase II relaxation activity. These results suggest that fractions C4 and C5 may represent important sources of potential antitumor agents due to their pronounced antitumor effects and low immune toxicity

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial

Objectives: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA). Methods: In this multicenter, randomized and parallel treatment trial, 346 patients with active RA (disease activity score (28 joints) [DAS28] (erythrocyte sedimentation rate [ESR]) > 5.1) were enrolled from 9 centers. In phase 1, patients received intensive treatment with methotrexate, leflunomide, and hydroxychloroquine, up to 36 weeks, until remission (DAS28 ≤ 2.6) or a low disease activity (2.6 < DAS28 ≤ 3.2) was achieved. In phase 2, patients achieving remission or low disease activity were followed up with randomization to 1 of 2 step-down protocols: leflunomide plus hydroxychloroquine combination or leflunomide monotherapy. The primary endpoints were good European League Against Rheumatism (EULAR) response (DAS28 (ESR) < 3.2 and a decrease of DAS28 by at least 1.2) during the intensive treatment and the disease state retention rate during step-down maintenance treatment. Predictors of a good EULAR response in the intensive treatment period and disease flare in the maintenance period were sought. Results: A good EULAR response was achieved in 18.7%, 36.9%, and 54.1% of patients at 12, 24, and 36 weeks, respectively. By 36 weeks, 75.4% of patients achieved good and moderate EULAR responses. Compared with those achieving low disease activity and a high health assessment questionnaire (HAQ > 0.5), patients achieving remission (DAS28 ≤ 2.6) and low HAQ (≤ 0.5) had a significantly higher retention rate when tapering the DMARDs treatment (P = 0.046 and P = 0.01, respectively). There was no advantage on tapering to combination rather than monotherapy. Conclusions: Remission was achieved in a proportion of patients with RA receiving prolonged intensive DMARD therapy. Low disease activity at the start of disease taper leads to less subsequent flares. Leflunomide is a good maintenance treatment as single treatment